WINNIPEG, MANITOBA -- (MARKET WIRE) -- September 07, 2006 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms, is pleased to announce that it has entered into an important efficacy study with its promising coating technology for reducing infections associated with central venous catheters (CVCs). KBI-4258 is a proprietary combination of the Company’s exclusively licensed dispersinB technology and an anti-microbial agent.
